Idenix Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Centre National De La Recherche Scientifique

Universitè De Montpellier

Pierre Fabre Medicament

Université Montpellier 2 Sciences Et Techniques

Msd International Gmbh

Houcine Rahali

David Dukhan

Jean-Laurent Paparin

Cyril B Dousson

Daniel Da Costa

Dominique Surleraux

Francois-Rene Alexandre

Christophe Parsy

Izzat Tiedje Raheem

Claire Pierra

Gilles J Gosselin

Thierry Convard

Michel Derock

Guillaume Brandt

Adel M Moussa

John D Schreier

David James Witter

David L Sloman

Phieng Siliphaivanh

Michelle R Machacek

Michael Hale Reutershan

Timothy J Henderson

Craig R Gibeau

Benjamin Alexander Mayes

Stéphane Poigny

Timothy John Hartingh

Alistair James Stewart

Yingchun Ye

El Bachir Kaloun

Chunhui Huang

Gilles Gosselin

Rémi Rabot

Karim Bedjeguelal

Ryan Quiroz

Sebastian Schneider

Serge Grisoni

Steven Mark Silverman

Charles S Yeung

Sulagna Sanyal

Shuhei Kawamura

David Annunziato Candito

Rachid Rahali

Hugues Bienayme

Aurélien Salanson

Jean-Francois Griffon

Pascaline Klein

Eric Tam

Bachir Kaloun El

Antoine Dumoulin

Jean-François Griffon

Murray Wan

Jonathan M E Hughes

Patrick S Fier

Christophe Claude Parsy

Hugues Bienhayme

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5 inhibitors

Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral aryl-amide phosphodiamide compounds

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral aliphatic ester prodrugs of tenofovir

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

2'-chloro nucleoside analogs for HCV infection

Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral prodrugs of tenofovir

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3',5&#x2032;-cyclic phosphate prodrugs for HCV infection

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.

Pyrroloquinoline derivatives and their use as protein kinases inhibitors

Growing community of inventors

Saint Laurent des Arbres, France

Houcine Rahali